血友病
精确的样本时间安排、标准化的凝血测试、抑制剂监测和可追溯的样本物流——Omega生态系统通过综合模式支持血友病临床试验。
血友病临床试验支持
在血友病研究中，实验室数据的价值不仅来自测试本身，还来自准确的样本时间安排、凝血参数标准化、抑制剂监测和患者旅程的正确管理。
Omega生态系统通过涵盖中心实验室服务、遗传分析、样本管理和居家采样流程的综合模式支持血友病A和B的研究。
从凝血测试到抑制剂监测、基因确认和样本物流，我们帮助申办方为血友病研究建立可追溯、方案合规的工作流程。
为何需要专门的实验室方法？
Critical laboratory outputs in hemophilia studies are often highly time-sensitive. Parameters such as Factor VIII (FVIII) and Factor IX (FIX) activity, inhibitor development, PK/PD evaluations, post-bleeding episode sampling, and response to prophylaxis require strict adherence to protocol-defined time windows.
Guidelines from the World Federation of Hemophilia also emphasize the importance of genetic evaluation, extended half-life factor products, and emerging treatment approaches in hemophilia management.
全面血液病学支持
凝血和安全实验室支持
在血友病研究中，常规安全性实验室评估和凝血测试应以综合方式规划。参数包括：
- Factor activity measurements (FVIII, FIX)
- Activated partial thromboplastin time (aPTT)
- Prothrombin time (PT)
- Complete blood count and biochemistry
are structured according to protocol-defined time points to ensure comparable data flow between clinical events, treatment administration, and laboratory results.
抑制剂监测
Inhibitor development is one of the most critical complications in hemophilia treatment. The Centers for Disease Control and Prevention (CDC) recommends that individuals with hemophilia or type 3 von Willebrand disease who use factor concentrates should be tested for inhibitors at least once a year.
在临床试验中，抑制剂检测计划、样本稳定性、实验室方法学和报告语言应从一开始就被标准化。
药代动力学和药效学
PK/PD采样在涉及因子替代产品、延长半衰期因子、非因子治疗和基因治疗的研究中可能至关重要。
- Pre-dose and post-dose time points
- Trough levels and peak levels
- Long-term response monitoring
基因和分子检测
血友病A和血友病B分别是与F8和F9基因相关的遗传性出血性疾病。
基因确认对于患者分层、家族史评估、变异解读和某些研究设计中的资格评估具有重要价值。在此背景下，与Omega Genetics的整合可以特别强调。
样本物流和居家采样
在血友病患者中，频繁访视负担、儿科人群、行动受限或出血后时间敏感采样等因素使居家采样和移动团队模式特别有价值。我们的综合方法确保从样本收集到实验室分析的可追溯、方案合规的工作流程。
凝血检测协调
方案对齐采样
针对因子活性、凝血参数和安全性实验室输出的结构化采样和报告工作流程。
综合分析
凝血检测与安全性评估、PK/PD采样和基因确认工作流程相协调。
可追溯报告
标准化报告，从样本采集到实验室结果交付的完整可追溯性。
Omega生态系统中的应用场景
How the Omega ecosystem delivers integrated support for hemophilia studies\u2014from coagulation testing to genetic confirmation and home sampling.
HelixLab
Coagulation & Factor Activity
Protocol-aligned FVIII/FIX activity assays (one-stage and chromogenic), aPTT, PT/INR, thrombin generation assays, and routine safety panels structured by defined time windows.
Omega Genetics
F8/F9 Variant Analysis
Full-length F8 gene sequencing including intron 1 and intron 22 inversion detection; F9 variant identification and inhibitor risk genotyping (HLA class I/II profiling).
Omega生物样本库
PK/PD Plasma Banking
Serial plasma aliquots at pre-dose, peak, and trough time points stored at -80\u00b0C for retrospective pharmacokinetic modeling and extended half-life product comparisons.
Omega Care
Home Bleeding Episode Sampling
Rapid-response mobile teams for time-sensitive post-bleed and pre-dose sampling at home; pediatric visit reduction through scheduled home factor activity monitoring.
Omega Bio
Bethesda Assay Standardization
Kit-based Nijmegen-modified Bethesda assay harmonization for inhibitor detection; lot-to-lot consistency ensuring reliable cross-site inhibitor incidence comparisons.
动物设施
Hemophilia A/B Animal Models
F8-knockout and F9-knockout mouse models for preclinical evaluation of factor replacement products, extended half-life therapeutics, and gene therapy candidates.